Ciclesonide (inhaled)

Ciclesonide is a novel inhaled corticosteroid used in equine medicine for the management of respiratory conditions characterized by airway inflammation. Unlike traditional inhaled corticosteroids that are active upon delivery, ciclesonide is a prodrug that requires enzymatic activation within the lungs to exert its anti-inflammatory effects. This unique characteristic provides potential advantages in terms of targeted drug activity and reduced local and systemic side effects. Ciclesonide has gained recognition in equine respiratory medicine as an effective treatment option for equine asthma syndrome, including conditions previously termed recurrent airway obstruction (RAO), heaves, and inflammatory airway disease (IAD).

The mechanism of action of ciclesonide involves a two-step process that distinguishes it from other inhaled corticosteroids. Ciclesonide itself has minimal glucocorticoid receptor binding activity when inhaled. However, once the drug reaches the lower airways, esterases present in the lung epithelium cleave ciclesonide to form desisobutyryl-ciclesonide, the active metabolite with potent anti-inflammatory properties. This active form then binds to glucocorticoid receptors within airway cells, initiating the cascade of anti-inflammatory effects characteristic of corticosteroids. These effects include reduced production of inflammatory mediators, decreased inflammatory cell recruitment, diminished airway swelling, and decreased mucus production. The requirement for local activation means that ciclesonide deposited in the mouth and upper airway remains largely inactive, potentially reducing risks of local side effects like oral candidiasis.

Ciclesonide for equine use is administered via metered-dose inhaler (MDI) through specialized equine aerosol delivery devices designed to facilitate inhalation therapy in horses. These devices create a holding chamber that captures the aerosolized medication, allowing the fine particles to be inhaled into the lungs as the horse breathes through the device. The small particle size of ciclesonide formulations promotes deep lung deposition where the drug can be activated and exert its effects on the lower airways. Multiple actuations are typically required per treatment session to deliver therapeutic doses to the equine respiratory tract, given the much larger lung capacity of horses compared to humans.

While ciclesonide's prodrug characteristics offer theoretical advantages, proper veterinary supervision remains essential for safe and effective use. Accurate diagnosis of equine asthma through appropriate diagnostic testing should precede treatment initiation, as other respiratory conditions may require different therapeutic approaches. The veterinarian will determine suitable dosing based on disease severity and individual patient factors, establish a treatment schedule, and monitor response through follow-up examinations. Horse owners must be trained in proper administration technique using equine delivery devices to ensure effective drug delivery to the lungs. Consistent treatment compliance and environmental management addressing allergen exposure are critical components of successful therapy.

The primary indication for inhaled ciclesonide in horses is the management of equine asthma syndrome, a spectrum of inflammatory respiratory conditions that significantly impact horse health and performance. Equine asthma encompasses conditions ranging from mild inflammatory airway disease (IAD) commonly observed in young performance horses to severe recurrent airway obstruction (RAO or heaves) causing pronounced respiratory distress in affected individuals. These conditions share underlying pathophysiology characterized by airway inflammation, bronchospasm, and excessive mucus accumulation that compromise respiratory function. Inhaled corticosteroids like ciclesonide address the inflammatory component of disease, providing foundation therapy for long-term management when combined with appropriate environmental modifications.

Horses with severe equine asthma, historically referred to as heaves or recurrent airway obstruction, represent a population that can benefit substantially from inhaled ciclesonide therapy. These horses manifest obvious respiratory signs including increased respiratory rate and effort at rest, pronounced nostril flaring, visible abdominal effort during expiration, and development of the characteristic heave line from chronic accessory muscle use. Severe disease typically develops in sensitized horses exposed to inhaled allergens in hay dust, mold spores, and barn environments. While environmental control remains fundamental to management, inhaled ciclesonide helps suppress the underlying inflammatory response and improve respiratory function. Many horses with severe disease require initial systemic corticosteroid therapy for stabilization before transitioning to inhaled maintenance treatment.

Inflammatory airway disease represents the milder portion of the equine asthma spectrum and is particularly common in young athletic horses. Studies have documented IAD prevalence exceeding 50% in some populations of racing and competition horses. Clinical manifestations include poor athletic performance, occasional coughing, exercise intolerance, and increased tracheal mucus without the severe respiratory distress seen in RAO. IAD can significantly compromise racing success and competition performance, making effective treatment essential for performance horses. Ciclesonide's prodrug characteristics, with activation occurring in the lungs rather than the upper airway, may offer advantages in minimizing local side effects while providing effective lower airway inflammation control.

Beyond typical equine asthma presentations, inhaled ciclesonide may be incorporated into treatment protocols for other conditions involving lower airway inflammation. Some veterinarians utilize inhaled corticosteroids in managing chronic bronchitis or persistent airway inflammation following resolution of respiratory infections. The medication may facilitate weaning from systemic corticosteroid therapy by maintaining airway inflammation control while reducing systemic drug exposure. In complex cases involving multiple contributing factors to respiratory compromise, ciclesonide inhalation therapy can serve as one component of a comprehensive management approach.

Selection of ciclesonide over other inhaled corticosteroids may be influenced by its unique prodrug characteristics, individual horse response to treatment, and practical considerations. The local activation mechanism theoretically reduces upper airway side effects and systemic absorption from drug deposited outside the lungs. For horses that have experienced oral complications with other inhaled corticosteroids or those requiring long-term therapy where cumulative side effect risk is a concern, ciclesonide may offer advantages. However, direct comparative studies in horses are limited, and individual response to different inhaled corticosteroids varies. The veterinarian will recommend the most appropriate medication based on the specific clinical situation and available evidence.

Dosing protocols for inhaled ciclesonide in horses must be established by a veterinarian based on the diagnosis, disease severity, and individual patient factors. Because ciclesonide formulations developed for human use are employed off-label in horses, veterinary expertise is essential for determining appropriate dosing. Unlike oral medications where dosing calculations are based strictly on body weight, inhaled medication dosing involves specifying the number of actuations from the metered-dose inhaler and treatment frequency, with the goal of delivering sufficient medication to the lower airways for inflammation control while minimizing unnecessary drug exposure.

Typical treatment protocols involve administering multiple actuations of the ciclesonide metered-dose inhaler through an equine aerosol delivery device. Common regimens utilize ciclesonide inhalers delivering a specified dose per actuation, with protocols often calling for administration once or twice daily depending on disease severity. Human ciclesonide inhalers are available in different strengths, and the veterinarian will specify the appropriate product and number of actuations based on the individual case. Initial treatment for active disease may employ higher doses or more frequent administration, with subsequent adjustment to the lowest effective maintenance dose as disease control is achieved.

Treatment duration varies substantially based on clinical circumstances. Acute exacerbations may require intensive short-term treatment for days to weeks, while horses with chronic equine asthma typically need long-term or indefinite maintenance therapy to prevent recurrence of respiratory signs. The chronic inflammatory nature of equine asthma means that many affected horses require ongoing inhaled corticosteroid treatment to maintain airway health. The veterinarian will establish follow-up schedules to assess treatment response through clinical examination and potentially endoscopic evaluation, bronchoalveolar lavage analysis, or lung function testing. Based on these objective assessments, therapy adjustments may be indicated.

Proper administration technique is crucial for effective inhaled medication delivery with ciclesonide, as it is with all inhaled corticosteroids. The metered-dose inhaler is attached to an equine aerosol delivery device, which is positioned over one nostril while the other nostril is held closed or occluded by the device design. After shaking the inhaler appropriately, it is actuated to release medication into the holding chamber. The horse then breathes through the device for several breaths, allowing the aerosolized particles to be carried into the lungs. This process is repeated for the prescribed number of actuations, then performed on the other nostril. The treatment environment should be calm and dust-free to optimize horse cooperation and avoid triggering respiratory symptoms during administration.

If a scheduled dose is missed, administer treatment as soon as remembered unless the next scheduled dose is approaching, in which case skip the missed dose and resume the regular schedule. Do not double doses to compensate for missed treatments, as this provides no benefit and may increase adverse effect risk. Consistent daily administration is important because inhaled corticosteroids work through gradual control of underlying airway inflammation rather than providing immediate symptom relief. Sporadic or inconsistent treatment results in suboptimal disease control and may allow inflammation to recur.

Completing the prescribed treatment regimen and maintaining consistency are essential for optimal outcomes with inhaled ciclesonide. Even when respiratory symptoms appear resolved, underlying inflammation may persist and will likely return if treatment is discontinued prematurely. The veterinarian will advise on appropriate approaches to dose reduction or discontinuation if these become appropriate. Environmental management measures to reduce allergen exposure must be maintained throughout treatment, as inhaled corticosteroid therapy cannot overcome ongoing exposure to respiratory irritants. Regular follow-up allows assessment of disease control, monitoring for adverse effects, and optimization of the overall management strategy.

Inhaled ciclesonide is generally well-tolerated in horses when used appropriately under veterinary supervision, with its prodrug characteristics potentially conferring a favorable side effect profile compared to some other inhaled corticosteroids. Because ciclesonide requires enzymatic activation in the lungs to become pharmacologically active, drug deposited in the mouth and upper airway remains largely inactive, theoretically reducing the risk of local side effects in these areas. However, horse owners should be aware of potential adverse effects and monitor appropriately during treatment.

Local effects in the oropharyngeal region are generally less problematic with ciclesonide than with other inhaled corticosteroids due to its prodrug nature. Oral candidiasis (thrush) and pharyngeal irritation, which can occur with traditional inhaled corticosteroids from upper airway drug deposition, appear to be less common with ciclesonide. Nevertheless, monitoring the oral cavity for signs of fungal overgrowth, such as white patches or changes in eating behavior, remains appropriate. Some horses may exhibit mild coughing during or immediately following medication administration. While reduced upper airway effects represent a potential advantage of ciclesonide, these effects are not entirely eliminated, and individual variation in response occurs.

Local immunosuppression within the lower respiratory tract represents a consequence of ciclesonide's intended therapeutic action. While suppression of airway inflammation provides clinical benefit, it may theoretically increase susceptibility to respiratory infections. Horses on long-term inhaled ciclesonide should be monitored for signs of respiratory infection including fever, nasal discharge, increased coughing, or changes in respiratory pattern. If infection develops during treatment, veterinary evaluation determines whether temporary discontinuation of inhaled therapy is appropriate while addressing the infection. The clinical decision must balance infection risk against the consequences of losing inflammation control.

Systemic side effects are generally less common and less severe with inhaled ciclesonide compared to systemic corticosteroid administration due to lower total body exposure. The active metabolite of ciclesonide that does reach systemic circulation is highly protein-bound, further reducing systemic glucocorticoid activity. However, some systemic absorption occurs, and horses receiving high doses or extended treatment courses may experience effects similar to those seen with other corticosteroids. These can include increased infection susceptibility, effects on wound healing, and rarely, alterations in glucose metabolism or adrenal function. Horses with metabolic conditions such as equine metabolic syndrome or pituitary pars intermedia dysfunction warrant careful monitoring during any corticosteroid therapy.

Serious adverse reactions requiring immediate veterinary attention are uncommon with inhaled ciclesonide but should be recognized. Signs of severe allergic reaction, acute respiratory distress, or significant behavioral changes warrant prompt evaluation. While laminitis risk is substantially lower with inhaled corticosteroid therapy than systemic administration, it remains a concern in predisposed horses. Any signs of foot pain, reluctance to move, increased digital pulses, or heat in the feet should be reported immediately. Contact the veterinarian also if expected clinical improvement does not occur, if symptoms worsen during treatment, or if new concerning signs develop.

Inhaled ciclesonide is contraindicated in horses with known hypersensitivity to ciclesonide, its active metabolite, other corticosteroids, or any components of the inhaler formulation. Horses that have experienced allergic or adverse reactions to inhaled medications, including other inhaled corticosteroids, should be carefully evaluated before ciclesonide therapy, though cross-reactivity between different corticosteroid preparations is not universal. Signs of hypersensitivity may include acute worsening of respiratory symptoms, urticaria, facial swelling, or other allergic manifestations following administration. Any history of medication adverse reactions should be communicated to the veterinarian before initiating treatment.

Active respiratory infections, particularly fungal infections of the respiratory tract, represent significant contraindications to inhaled corticosteroid therapy including ciclesonide. Corticosteroid-induced immunosuppression in the airways could worsen existing infections or allow opportunistic pathogens to proliferate. Bacterial respiratory infections should generally be treated with appropriate antimicrobial therapy before starting or resuming inhaled corticosteroid treatment. Viral respiratory infections should resolve before initiation of inhaled ciclesonide. If a horse on ciclesonide treatment develops signs of respiratory infection, veterinary evaluation is needed to determine appropriate management, which may include temporary discontinuation of corticosteroid therapy.

Horses with certain metabolic and endocrine disorders require careful evaluation before initiating inhaled ciclesonide, and in some cases the medication may be relatively contraindicated. Horses with pituitary pars intermedia dysfunction (PPID, equine Cushing's disease) already exhibit elevated cortisol levels, compromised immune function, and metabolic disturbances that could potentially be exacerbated by exogenous corticosteroid exposure. Similarly, horses with equine metabolic syndrome (EMS) may be susceptible to worsening insulin dysregulation. The risk of laminitis in these predisposed populations must be carefully considered against the need for respiratory inflammation control. If inhaled corticosteroid therapy is deemed necessary in metabolically compromised horses, use of the lowest effective dose with vigilant monitoring is essential.

Additional clinical situations may contraindicate ciclesonide use or require particular caution. Horses with active laminitis or recent laminitis episodes should not receive corticosteroid therapy unless absolutely necessary under close veterinary supervision. Pregnant mares should be treated with caution, as effects of inhaled ciclesonide on equine pregnancy have not been established. Horses with systemic fungal infections or tuberculosis should not receive corticosteroid therapy of any route. Practical limitations such as inability to effectively administer inhaled medication due to severe behavioral issues, significant nasal obstruction, or lack of appropriate delivery equipment may also preclude use of inhaled ciclesonide in individual patients.

Understanding potential drug interactions is important when using inhaled ciclesonide as part of a comprehensive respiratory management program. While the localized delivery and prodrug characteristics of ciclesonide result in reduced systemic exposure compared to other corticosteroid administration routes, some systemic absorption of the active metabolite occurs and may contribute to interactions with other medications. Additionally, ciclesonide is often used alongside other respiratory medications, and understanding how these agents work together optimizes disease management.

Concurrent use of inhaled ciclesonide with other corticosteroids results in cumulative corticosteroid exposure that may increase the risk of adverse effects. Horses receiving systemic corticosteroids such as dexamethasone or prednisolone may be transitioned to inhaled maintenance therapy, but simultaneous use should be carefully managed. The veterinarian will establish appropriate protocols for overlapping therapy during transitions and for tapering systemic treatment while maintaining or initiating inhaled therapy. Topical corticosteroid preparations applied elsewhere on the body also contribute to total corticosteroid load and should be considered in the overall assessment of corticosteroid exposure.

Inhaled ciclesonide is commonly combined with bronchodilator medications for comprehensive management of equine asthma syndrome. Inhaled beta-agonist bronchodilators such as albuterol or anticholinergic bronchodilators such as ipratropium provide rapid relief of bronchospasm and may be used for acute symptom relief or in routine combination with daily inhaled corticosteroid treatment. When multiple inhaled medications are prescribed, the bronchodilator is typically administered first to open the airways, potentially enhancing delivery of the subsequently administered corticosteroid to the lower respiratory tract. The veterinarian will provide specific guidance on timing and technique when multiple inhaled medications are used.

NSAID use in horses receiving inhaled ciclesonide warrants consideration, as the combination of corticosteroids and NSAIDs can increase risk of gastrointestinal complications. While this risk is lower with inhaled corticosteroid therapy than systemic administration due to reduced systemic exposure, horses on long-term inhaled ciclesonide who also require NSAID therapy may benefit from gastroprotective measures. Standard recommendations to avoid simultaneous corticosteroid and NSAID use or provide adequate washout periods apply, though clinical significance is reduced with the lower systemic absorption achieved through inhaled delivery. Any concurrent NSAID use should be discussed with the veterinarian managing respiratory treatment.

Competition horses must consider regulatory implications of ciclesonide use, as inhaled corticosteroids are prohibited or controlled substances under most competition rules. Although ciclesonide's metabolic pathway differs from other inhaled corticosteroids, it is subject to similar regulatory scrutiny. Owners and trainers of competition horses should maintain accurate medication records and consult current FEI, USEF, or applicable racing commission regulations. The veterinarian can provide guidance on expected detection times and recommended withdrawal periods, but ultimate compliance responsibility rests with the owner and trainer. Individual variation in drug metabolism may affect detection times, so when eligibility is uncertain, horses should not compete.

Appropriate monitoring during inhaled ciclesonide therapy helps ensure treatment efficacy and allows early identification of adverse effects. Horse owners should observe respiratory function daily, noting coughing frequency, breathing rate and effort, exercise tolerance, and overall respiratory comfort. Clinical improvement with inhaled corticosteroids develops gradually over days to weeks of consistent treatment rather than immediately. The veterinarian will schedule follow-up examinations to objectively assess treatment response, potentially including endoscopic airway evaluation, bronchoalveolar lavage cytology, or pulmonary function testing. These objective measures guide therapy optimization and confirm adequate disease control is being achieved.

Special populations of horses require additional precautions when using inhaled ciclesonide. Foals and young horses have different drug metabolism characteristics than mature horses, and pediatric dosing guidelines for inhaled corticosteroids in equines are not well established. Geriatric horses, particularly those with PPID, face heightened risks from corticosteroid exposure and require careful monitoring. Pregnant mares should receive inhaled corticosteroids only when therapeutic benefits clearly outweigh potential risks to the mare and fetus. Horses with history of laminitis or metabolic conditions predisposing to laminitis need close monitoring of hoof health during treatment. Individual horse factors should guide treatment decisions and determine appropriate monitoring intensity.

Competition and performance horse considerations are particularly important for inhaled corticosteroid use. Ciclesonide is a prohibited or controlled substance under FEI regulations, USEF rules, and racing commission guidelines. While ciclesonide has a unique metabolic profile as a prodrug, it is still subject to detection and regulatory action. Horse owners must check current regulations from the relevant governing body, maintain detailed treatment records documenting dates, doses, formulations, and batch numbers, and allow adequate time between last treatment and competition. Detection time differs from withdrawal time, and individual metabolic variation may prolong detection in some horses. When eligibility is uncertain, do not compete.

Environmental management remains essential alongside inhaled ciclesonide for effective equine asthma control. Medication cannot overcome ongoing exposure to allergens and respiratory irritants, and environmental control is fundamental to disease management. Effective measures include soaking or steaming hay to reduce respirable particles, using low-dust bedding alternatives, improving barn ventilation, removing horses from enclosed spaces during stall cleaning and sweeping, and maximizing turnout time. Horses with severe disease may benefit from complete turnout management. The veterinarian can provide specific environmental recommendations tailored to individual circumstances and facilities.

Long-term inhaled ciclesonide use requires periodic veterinary reassessment. While inhaled therapy and ciclesonide's prodrug characteristics reduce adverse effect risk compared to systemic corticosteroids, prolonged use still requires ongoing evaluation. Regular assessment determines whether continued treatment remains appropriate, whether dosing adjustments are indicated, and whether the management approach needs modification. Treatment goals should be periodically reviewed, environmental management reinforced, and overall horse health assessed. Do not adjust inhaled corticosteroid dosing without veterinary guidance.

Proper storage of ciclesonide metered-dose inhalers maintains medication stability and ensures consistent drug delivery with each actuation. Inhalers should be stored at controlled room temperature, typically between 59°F and 77°F (15°C and 25°C), protected from extremes of heat and cold that could affect the pressurized canister or medication stability. Avoid storage in vehicles, unheated tack rooms, or other locations where significant temperature fluctuations occur. Light exposure should be minimized by storing inhalers in their original packaging until ready for use. Humidity can affect inhaler function, so dry storage conditions are preferred.

Metered-dose inhalers are pressurized containers requiring appropriate handling precautions. Do not puncture, crush, or incinerate inhaler canisters, and avoid exposure to temperatures exceeding 120°F (49°C) that could cause the container to rupture. Before each use, shake the inhaler well to ensure proper suspension of the medication within the propellant. Prime new inhalers or those that have not been used for the period specified by the manufacturer by releasing test actuations into the air before administering medication to the horse. Track remaining doses using the integrated dose counter if present, and do not continue using inhalers beyond their labeled number of actuations, as remaining doses may not deliver therapeutic amounts of medication.

The equine aerosol delivery device used with the ciclesonide inhaler requires regular cleaning and maintenance for proper function. After each treatment session, wipe the device to remove any medication residue and allow it to dry completely. Periodically wash the device with mild soap and warm water according to manufacturer instructions, ensuring thorough drying before next use. Inspect the device regularly for cracks, damage to valves, or deterioration of seals that could compromise drug delivery. The interface between the inhaler and spacer device should seat properly to ensure medication enters the chamber rather than escaping. Replace delivery devices according to manufacturer recommendations or when damage is observed.

Check expiration dates on ciclesonide inhalers before use, and do not use products beyond their expiration date, as medication potency and delivery consistency cannot be guaranteed. Expired products should be disposed of according to local pharmaceutical waste regulations and replaced with fresh medication. Keep all medications secured away from children and other animals to prevent accidental exposure or misuse. Maintain medications in original packaging with labeling intact to preserve identification, expiration date information, and lot numbers for treatment records. Proper storage and handling practices ensure that each treatment delivers the intended medication dose effectively.

Draft horse breeds including Clydesdales, Percherons, Shires, and Belgians present specific considerations for inhaled ciclesonide therapy related to their larger body size and respiratory tract dimensions. The substantially larger lungs of draft breeds may require dose adjustments to achieve therapeutic concentrations in the airways comparable to those achieved in lighter breeds with standard protocols. Higher total doses delivered through more actuations or more frequent treatment sessions may be necessary. Equipment fit is also relevant; ensure that equine aerosol delivery devices fit properly over the larger nostrils of draft horses to create an effective seal for drug delivery. Despite their size, draft horses can develop equine asthma and generally respond to inhaled corticosteroid therapy when appropriate dosing is achieved.

Light horse breeds such as Thoroughbreds, Arabians, Quarter Horses, and their crosses comprise the majority of horses receiving inhaled ciclesonide for respiratory conditions. Inflammatory airway disease is particularly prevalent in young racing and performance horses of these breeds. Standard dosing protocols typically apply to light horses, though individual variation in treatment response occurs and adjustments may be needed. Some hot-blooded individuals may be reactive during the treatment process; patient, consistent handling and establishing a positive routine around medication administration helps improve cooperation over time. Creating a calm environment for treatment supports both effective drug delivery and horse acceptance.

Ponies and miniature horses require dosing considerations for inhaled ciclesonide therapy. While inhalation therapy dosing is not strictly body-weight-based, the smaller airway dimensions of ponies and miniatures may result in different relative drug exposure compared to full-sized horses receiving equivalent numbers of actuations. Standard equine delivery devices may not fit properly on small muzzles, potentially compromising medication delivery, and pony-specific equipment or modified techniques may be needed. Ponies have higher prevalence of equine metabolic syndrome and associated laminitis risk, making vigilant monitoring essential during any corticosteroid therapy, even though inhaled administration presents lower systemic risk than other routes.

Breed-specific health conditions warrant consideration when planning inhaled corticosteroid therapy. Warmbloods demonstrate relatively high prevalence of equine asthma and commonly require long-term respiratory management. Friesians show documented sensitivity to certain medications and may warrant conservative dosing approaches with careful monitoring for adverse effects. Quarter Horses and related breeds with known genetic conditions such as HYPP do not have specific documented concerns with inhaled ciclesonide, though overall health status affects treatment decisions. No specific contraindications to inhaled ciclesonide have been established for Arabian horses, Appaloosas, or other breeds based on breed identity alone. Treatment protocols should be individualized based on each horse's response and any concurrent health considerations.

Within the class of inhaled corticosteroids for equine respiratory disease, several alternatives to ciclesonide are available with different characteristics. Fluticasone propionate is a widely used inhaled corticosteroid with high glucocorticoid potency and established efficacy in equine asthma management. Beclomethasone dipropionate represents another commonly employed option with a long history of use in horses. Budesonide offers an alternative with high first-pass hepatic metabolism that limits systemic exposure from absorbed drug. Selection among these inhaled corticosteroids may depend on individual horse response, veterinarian experience and preference, availability, and cost considerations. Some horses that respond inadequately to one inhaled corticosteroid may show improved disease control when switched to an alternative, making therapeutic trial of different options reasonable in refractory cases.

Systemic corticosteroids provide an alternative approach for horses with severe equine asthma or those unable to receive effective inhaled therapy. Dexamethasone and prednisolone are commonly administered systemically, delivering potent anti-inflammatory effects throughout the body. Systemic corticosteroid therapy is often necessary for initial stabilization of horses with severe respiratory disease before transitioning to inhaled maintenance treatment. It may also be appropriate when inhaled administration is not feasible due to horse behavior, equipment unavailability, or other practical limitations. However, systemic corticosteroids carry substantially higher risks of adverse effects including laminitis, immunosuppression, and metabolic disturbances. The therapeutic goal in most cases is to achieve disease control with systemic treatment then transition to inhaled therapy for maintenance.

Complementary therapies support comprehensive management of equine respiratory conditions alongside inhaled corticosteroid treatment. Inhaled bronchodilators including beta-agonists like albuterol and anticholinergics like ipratropium provide rapid bronchospasm relief and are frequently combined with inhaled corticosteroids. Environmental management through dust reduction, improved ventilation, hay treatment methods, and feeding practice modifications remains the cornerstone of reducing allergen exposure and is essential regardless of pharmacological therapy. Omega-3 fatty acid supplementation may provide modest anti-inflammatory support. When considering substituting medications or adding therapies to an established regimen, consult the veterinarian to ensure safe and appropriate integration with the current management plan.